Regentis Biomaterials Ltd. (RGNT) saw its stock plummet 12.12% intraday on Thursday, following its debut on the NYSE American.
The decline came after the company priced its initial public offering at $8 per share, raising $10 million in gross proceeds. The stock opened at $7.40 and fell further to $7.06, reflecting investor skepticism about its market entry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.